Inventor · disambiguated record
Judith Campisi
Also filed as: CAMPISI JUDITH
30 granted patents·13 pending applications·203 citations·filing 1994–2023
97Inventor score
Files withBUCK INST RES AGING19UNITY BIOTECHNOLOGY INC7UNIV CALIFORNIA5BUCK INST FOR RES ON AGING3BUCK INSTITUTE FOR RES AND AGING2
Top patents by PatentIndex Score
43 records- 0198US10010546B2Treatment of ophthalmic conditions by selectively removing senescent cells from the eyeBUCK INST RES AGING·Filed 2017·Granted Jul 3, 2018·23 cites·11 claims
- 0297US9849128B2Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cellsBUCK INST RES AGING·Filed 2017·Granted Dec 26, 2017·24 cites·15 claims
- 0396US9993472B2Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2BUCK INST RES AGING·Filed 2015·Granted Jun 12, 2018·20 cites·7 claims
- 0496US9980962B2Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary diseaseBUCK INST RES AGING·Filed 2017·Granted May 29, 2018·6 cites·8 claims
- 0596US9855266B2Treatment for osteoarthritis by intra-articular administration of a cis-imidazolineBUCK INST RES AGING·Filed 2017·Granted Jan 2, 2018·12 cites·14 claims
- 0695US10328073B2Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Jun 25, 2019·9 cites·16 claims
- 0795US10130628B2Treatment of joint painUNITY BIOTECHNOLOGY INC·Filed 2017·Granted Nov 20, 2018·6 cites·8 claims
- 0894US10478432B2Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eyeBUCK INST RES AGING·Filed 2018·Granted Nov 19, 2019·7 cites·18 claims
- 0994US9901080B2Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cellsBUCK INST RES AGING·Filed 2016·Granted Feb 27, 2018·16 cites·20 claims
- 1092US10258618B2Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimenBUCK INST RES AGING·Filed 2018·Granted Apr 16, 2019·5 cites·17 claims
- 1191US10328058B2Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaquesMAYO FOUND MEDICAL EDUCATION & RES·Filed 2017·Granted Jun 25, 2019·5 cites·12 claims
- 1291US10213426B2Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell populationBUCK INST RES AGING·Filed 2017·Granted Feb 26, 2019·5 cites·13 claims
- 1390US11351167B2Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissueBUCK INST RES AGING·Filed 2019·Granted Jun 7, 2022·1 cites·14 claims
- 1490US10478433B2Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision lossUNITY BIOTECHNOLOGY INC·Filed 2018·Granted Nov 19, 2019·4 cites·20 claims
- 1586US10279018B2Immunogenic compositions for inducing an immune response for elimination of senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2013·Granted May 7, 2019·3 cites·14 claims
- 1686US9884065B2Inhibiting activity of senescent cells using a glucocorticoidBUCK INST RES AGING·Filed 2016·Granted Feb 6, 2018·5 cites·15 claims
- 1782US12285427B2Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitorBUCK INST RES AGING·Filed 2023·Granted Apr 29, 2025·0 cites·4 claims
- 1882US9901081B2Transgenic mouse for determining the role of senescent cells in cancerBUCK INST RES AGING·Filed 2016·Granted Feb 27, 2018·2 cites·12 claims
- 1979US11980616B2Treating liver disease by selectively eliminating senescent cellsBUCK INST RES AGING·Filed 2020·Granted May 14, 2024·0 cites·23 claims
- 2079US2019343832A1Therapy for removing senescent cells and treating senescence-associated disease using an mdm2 inhibitorUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 2178US11963957B2Treating cardiovascular disease by selectively eliminating senescent cellsBUCK INST RES AGING·Filed 2020·Granted Apr 23, 2024·0 cites·24 claims
- 2277US2021030752A1Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissueBUCK INST RES AGING·Filed 2020·Application pending·0 cites
- 2372US2022096466A1Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agentsBUCK INSTITUTE FOR RES AND AGING·Filed 2021·Application pending·0 cites
- 2469US8846629B2Id-1 and Id-2 genes and products as therapeutic targets for treatment of breast cancer and other types of carcinomaDESPREZ PIERRE-YVES·Filed 2008·Granted Sep 30, 2014·0 cites·9 claims
- 2567US7429457B2Id-1 and Id-2 genes and products as markers of epithelial cancerUNIV CALIFORNIA·Filed 2001·Granted Sep 30, 2008·2 cites·5 claims
- 2665US8030012B2Id-1 and Id-2 genes and products as markers of epithelial cancerUNIV CALIFORNIA·Filed 2006·Granted Oct 4, 2011·0 cites·7 claims
- 2764US6409648B1Polynucleotides encoding TRF1 binding proteinsUNIV CALIFORNIA·Filed 2000·Granted Jun 25, 2002·2 cites·10 claims
- 2863US10655144B2Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cellsBUCK INST RES AGING·Filed 2018·Granted May 19, 2020·0 cites·10 claims
- 2962US2019201510A1Passive vaccine for elimination of senescent cellsUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 3061US8809291B2Id-1 gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinomaDESPREZ PIERRE-YVES·Filed 2011·Granted Aug 19, 2014·0 cites·6 claims
- 3161US5965543ASenescence responsive transcriptional elementGERON CORP·Filed 1997·Granted Oct 12, 1999·18 cites·12 claims
- 3258US2019269675A1Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agentsBUCK INSTITUTE FOR RES AND AGING·Filed 2019·Application pending·0 cites
- 3357US5491069ABiomarkers of cell senescenceUNIV CALIFORNIA·Filed 1994·Granted Feb 13, 1996·22 cites·14 claims
- 3457US2024216316A1Dihomo-gamma linolenic acid (dgla) is a novel senolyticBUCK INST RES AGING·Filed 2021·Application pending·0 cites
- 3551US2018193458A1Compositions and methods for treating senescence-associated diseases and disordersUNITY BIOTECHNOLOGY INC·Filed 2016·Application pending·0 cites
- 3649US2019000846A1Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque RegressionMAYO FOUND MEDICAL EDUCATION & RES·Filed 2018·Application pending·0 cites
- 3748US11814680B2Biomarkers for detecting senescent cellsUNIV WIEN BODENKULTUR·Filed 2018·Granted Nov 14, 2023·0 cites·12 claims
- 3848US2014335074A1Methods for improving medical therapiesBUCK INST FOR RES ON AGING·Filed 2012·Application pending·0 cites
- 3942US2006263809A1Method for sensitive measure of low level apoptosis in cellsRGENTS OF THE UNIVERSITY OF CA·Filed 2006·Application pending·0 cites
- 4042US2013288981A1Targeting senescent cells and cancer cells by interference with jnk and/or foxo4BUCK INST FOR RES ON AGING·Filed 2013·Application pending·0 cites
- 4138US5795728ABiomarkers of cell senescenceUNIV CALIFORNIA·Filed 1995·Granted Aug 18, 1998·6 cites·5 claims
- 4237US2020371122A1Biomarker for senescent cellsBUCK INST RES AGING·Filed 2018·Application pending·0 cites
- 4337US2013288980A1Targeting senescent and cancer cells for selective killing by interference with foxo4BUCK INST FOR RES ON AGING·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Judith Campisi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →